Jing Wu, M.D., Ph.D.
Dr. Wu is a staff clinician of Neuro-Oncology Branch (NOB), which is a collaboration between NCI and NINDS. She is a board-certified Neurologist and sub-specialty fellowship-trained Neuro-Oncologist with a PhD research training in Neuroscience. She is interested in translational research in Neuro-Oncology focusing on developing preclinical testing and hypothesis-based clinical trials of glioma treatments.
Phase I Trial of TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and GlioblastomaOpen - RecruitingNCI Protocol ID NCI-17-C-0009Investigator Jing Wu, M.D., Ph.D.
Selected Key Publications
Changes in nitric oxide synthase isoforms in the spinal cord of rat following induction of chronic arthritis.Experimental Brain Research. 118: 457-465, 1998. [ Journal Article ]
- Pain. 94: 47-58, 2001. [ Journal Article ]
- Journal of Neuro-Oncology. 103: 791-796, 2011. [ Journal Article ]
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.Cell Rep. 13: 2353-2361, 2015. [ Journal Article ]
Biology and management of ependymoma.Neuro-Oncology. In press: 2016. [ Journal Article ]
She is certified both by the American Board of Psychiatry and Neurology (ABPN) in Neurology and United Council for Neurologic Subspecialties (UCNS) in Neuro-Oncology. Dr. Wu has published more than 38 peer reviewed articles and serves as an invited reviewer for many journals. She has received many academic and research awards including William James Miller Endowed Fellowship Award in Neuro-oncology and an NIH/NCI Paul Calabresi Clinical Oncology Scholar Award. She specializes in CNS neoplasms and neurological complications of systemic cancers. Her research focuses on developing preclinical studies in discovering novel therapies for glioma patients.
|Robert Y. Chen B.S.||Special Volunteer|
|Yu-Ting Su Ph.D.||Visiting Fellow|